Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US court vacates Suboxone injunction

Executive Summary

Dr Reddy’s Laboratories plans to resume its launch activities of the first generic of Indivior’s Suboxone (buprenorphine/naloxone) sublingual film formulation “as soon as permitted” after a US Court of Appeals vacated and remanded a district court’s preliminary injunction in a majority 2-1 decision. Appeals court judge Pauline Newman offered a dissenting opinion. As Generics bulletin went to press, Dr Reddy’s had not announced a launch.

You may also be interested in...



Alvogen and Dr Reddy’s US Suboxone Rivals Face Off Against Sandoz’ Authorized Generic

Alvogen and Dr Reddy’s have launched generic versions of Indivior’s Suboxone in the US, after the Supreme Court denied the originator’s attempt to further frustrate generic launches. But these two versions will compete with an authorized generic launched by Indivior through Sandoz.

Indivior Sets Out Next Steps As It Braces For Suboxone Rivals

Indivior is exhausting all its options to try and stop the impending launch of US generic rivals to Suboxone from 19 February, including petitioning the country’s Supreme Court to intervene. But even if Dr Reddy’s and Alvogen do launch their versions next week, the originator is planning to combat them with an authorized generic.

US Suboxone Generics Likely To Hit On Monday: Here’s All You Need To Know

Generic competition to Indivior’s Suboxone is poised to hit on Monday, following the latest court decision in a saga that has twisted and turned.

Latest News
See All
UsernamePublicRestriction

Register

GB001531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel